Venue
Netherlands Architecture Institute (NAI), Museumpark 25
3015 CB Rotterdam, The Netherlands
Phone: +31 10 44 01 200
www.nai.nl

Abstracts
Abstracts will be accepted till 31st March 2010.
Abstracts should be submitted by email as a word document, should use 12 point Arial font and
must not exceed 300 words. Abstracts will be reviewed by the scientific committee and those
with the highest scores will be selected for presentation as oral papers.
Successful abstract authors will be invited to register for the symposium at the early bird rate of
125 Euros. Please send your abstract by 31st March 2010 to: issc@statusplus.nl

Registration Deadlines
Delegates are advised to book early to avoid disappointment as places are limited to 160
deleagtes. The early bird registration fee of 125 Euros, including the membership fee for ISSC
for 2010, applies until 31st March 2010. After 31st March 2010 the registration fee will be 175
Euros. On-site registration, only in the event that there are still places available, will be 250
Euros. Cancellations before 1st May 2010 will be refunded (less 25 Euro cancellation fee) after
the meeting. After 1st May 2010 no refund will be possible.

To register please visit: www.issc.nu

Faculty
Johannes Blitzer, M.D., Switzerland
Darja Brandenburg, Ph.D., UK
Luca Incrocci, M.D., Ph.D., The Netherlands
Emmanuele Jannini, M.D., Italy
Susanne Singer, Ph.D., Germany

Scientific Committee
Isabel D. White, Ph.D., UK, Chair
Luca Incrocci, M.D., Ph.D., The Netherlands
Antonio Martin Morales, M.D., Spain
Pierre Bondil, M.D., France
Woet Gianotten, M.D., The Netherlands

Organizing secretariat
Status Plus Conferences
P.O. Box 94, 1520 AB Wormerveer, The Netherlands
Phone: +31 75 64 76 370
Fax: +31 75 64 76 371
E-mail: issc@statusplus.nl

Sponsored by
Lilly
Answers That Matter.
Dear colleagues, dear friends

It is a great pleasure to invite you to the 2nd Rotterdam Symposium on Cancer and Sexuality that will be held in Rotterdam, The Netherlands, on 4th June 2010.

One of the hidden consequences of cancer is its impact on sexuality and the development of treatment induced sexual problems. Patients often feel unable to communicate with their clinical team about sexual matters, and even when they do, there may be a lack of appropriately trained personnel to work with them. This can have a hugely negative impact on their quality of life, even when the cancer has been treated successfully. As a response to such observations, a multidisciplinary international society was formed in 2002 to focus on this important area of clinical care, the International Society for Sexuality and Cancer (ISSC). The principal aim of the society is to heighten awareness about cancer and sexual medicine by fostering research, encouraging training and providing a forum at international meetings for discussion.

This 2nd Rotterdam Symposium on Cancer and Sexuality, Controversies in Cancer and Sexual Function, will be of interest to all those who work with people whose sexual lives have been affected by cancer and its management. The programme has topics of relevance to doctors, nurses and psychological therapists who support individuals and couples experiencing sexual and relationship difficulties as a direct or indirect consequence of their cancer treatment. More specifically this symposium explores challenging, controversial and neglected aspects of sexual recovery in oncology including: penile rehabilitation strategies, hormone replacement for low desire in hormone responsive cancers, sexuality and body image in head and neck cancer and the restoration of intimacy in serious illness.

We hope that this symposium will give health-care providers from different disciplines, cultures and nationalities the possibility to share their knowledge and expertise on this challenging topic.

We look forward to welcoming you all in Rotterdam to be part of this scientific experience.

Luca Incrocci, President ISSC
Isabel White, Chair Scientific Committee

Preliminary Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.00</td>
<td>Registration and Coffee/tea</td>
</tr>
<tr>
<td>10.00-10.15</td>
<td>Welcome</td>
</tr>
<tr>
<td>10.15-10.45</td>
<td>Chair: Isabel White</td>
</tr>
<tr>
<td>10.15-10.45</td>
<td>Johannes Bitzer</td>
</tr>
<tr>
<td>10.45-11.15</td>
<td>Darja Brandenburg</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td>Proffered papers: Session 1</td>
</tr>
<tr>
<td>12.45-13.45</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.45-14.15</td>
<td>Chair: Luca Incrocci</td>
</tr>
<tr>
<td>13.45-14.15</td>
<td>Johannes Bitzer</td>
</tr>
<tr>
<td>14.15-15.45</td>
<td>Proffered papers: Session 2</td>
</tr>
<tr>
<td>15.45-16.15</td>
<td>Coffee/tea break</td>
</tr>
<tr>
<td>16.15-16.45</td>
<td>Emmanuele Jannini</td>
</tr>
<tr>
<td>16.45-17.15</td>
<td>Luca Incrocci</td>
</tr>
<tr>
<td>16.45-17.45</td>
<td>Susanne Singer</td>
</tr>
<tr>
<td>17.45</td>
<td>Adjourn</td>
</tr>
<tr>
<td>17.50-18.30</td>
<td>Reception</td>
</tr>
</tbody>
</table>

Is androgen supplementation feasible in the hypogonadal patient treated for prostate cancer?